Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction

Conclusion The present study has demonstrated that a single dose of pegfilgrastim is comparable to filgrastim in terms of the timing and efficacy of PBSC harvest and could potentially spare the patient 6 days of filgrastim injections. In addition, ours is the first study to compare these growth factors using vinorelbine/cyclophosphamide as mobilization chemotherapy. Micro-Abstract The current standard of care for transplant-eligible multiple myeloma (MM) patients is novel agent-based (NA) induction followed by high-dose chemotherapy and autologous stem cell transplant (ASCT). This study analyzed the efficacy of pegfilgrastim in stem cell (PBSC) mobilization compared to filgrastim, exclusively after NA-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at 2 transplant centers in Singapore who received NA-based induction chemotherapy, PBSC mobilization with vinorelbine/cyclophosphamide, high-dose melphalan conditioning and ASCT. This study demonstrates that a single dose of pegfilgrastim is comparable to filgrastim in terms of the timing and efficacy of PBSC harvest and could potentially spare the patient of 6 days of filgrastim injections.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research